Search

Saposin C

BXQ-350 consists of Saposin C and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. … Recombinant, non-glycosylated Saposin C is an active ingredient of BXQ-350, which is a novel, investigational anti-neoplastic therapy.

SynOV1.1

SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech. … SynOV1.1 is under investigation in clinical trial NCT04612504 (Synov1.1 Intratumoral Injection Study).

Probiorinse

[L16368] This strain of bacteria is said to have salubrious effects on the microbiome of the nasal cavity and sinuses.[A220193] … Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation solution that contains the probiotic bacteria Lactococcus lactis W136.

Elvucitabine

Neisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen

Allocetra

With infusion, the body's macrophages and dendritic cells can feed on these early apoptotic Allocetra cells and thus result in the macrophages and dendritic cells releasing fewer cytokine alert signals … Allocetra is a novel therapy where billions of early apoptotic cells are infused into the bloodstream of a patient, using the body's own natural regulation mechanisms to rebalance an unbalanced immune

AVR-RD-02

AVR-RD-02 is being investigated in Gaucher Disease.[L45958] … AVR-RD-02 is an investigational _ex vivo_ lentiviral gene therapy developed by AVROBIO Inc.

NV1020

NV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.

DFV890

DFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic

Bethanidine

A guanidinium antihypertensive agent that acts by blocking adrenergic transmission.